| Ytd | -37.99% | |
| 1y | -89.86% |
| Open | 0.91 | Prev Close | 0.90 | Low | 0.88 | High | 0.95 | Mkt Cap | 5.07M |
| Vol | 6.63K | Avg Vol | 2.32M | EPS | -3.56 | P/E | -0.26 | Forward P/E | N/A |
| Beta | -0.38 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.91 | 200-d Avg | 1.15 | 1yr Est | 0.00 |
BGMS News
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's
Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans
Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) and Peak Pharmaceuticals (OTCMKTS:PKPH - G
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
Bio Green Med Solution, Inc. (NASDAQ:BGMS) shares are trading higher Friday after the company announ
Solidion Technology, Inc. (NASDAQ: STI) rose 50.55% in pre-market trading on Friday after announcing
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge
Creation of a next-generation environmental platform: The proposed transaction brings together essen
KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS;
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the
Syros Pharmaceuticals (NASDAQ: SYRS - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS -
Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) and Achaogen (OTCMKTS:AKAOQ - Get Free Rep
Calliditas Therapeutics AB (publ) (NASDAQ: CALT - Get Free Report) and Cyclacel Pharmaceuticals (NAS
KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS
